Sionna Therapeutics, Inc. - 8-K Filing
Sionna Therapeutics reported a net loss of $26.8 million for Q1 2026 compared to $16.5 million in the same period last year due to increased R&D and G&A expenses as it advances its clinical pipeline, including completing enrollment in the Phase 2a trial for SION-719. The company holds $289.9 million in cash and expects this balance to fund operations through 2028. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $SION